Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina.
Duke Cancer Institute and the Duke Prostate and Urologic Cancer Center, Durham, North Carolina.
Clin Cancer Res. 2019 Feb 1;25(3):901-903. doi: 10.1158/1078-0432.CCR-18-2491. Epub 2018 Sep 11.
Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer..
伊帕替膦联合阿比特龙治疗 PTEN 缺失前列腺癌在转移性去势抵抗性前列腺癌（mCRPC）患者的随机 II 期研究中改善了无进展生存期，为 Akt 和雄激素受体（AR）通路之间的相互激活提供了临床证据。这些数据为在前列腺癌中靶向 PTEN 缺失提供了新的依据。
